Review
doi: 10.1016/s0167-5273(00)00282-5.
Failed thrombolysis in myocardial infarction
Affiliations
- PMID: 11054500
- DOI: 10.1016/s0167-5273(00)00282-5
Item in Clipboard
Review
Failed thrombolysis in myocardial infarction
Int J Cardiol.
2000 Aug.
Abstract
Prompt treatment with thrombolytic therapy in acute myocardial infarction has been proven to reduce infarct size and mortality. However, reperfusion fails to occur in 30-50% of patients, either due to impaired epicardial artery flow or microvascular occlusion, with these patients experiencing a higher morbidity and mortality. We review the diagnosis and management of failed thrombolysis in acute myocardial infarction.
Similar articles
-
Advances in antithrombotic therapy of acute myocardial infarction.Am Heart J. 1999 Aug;138(2 Pt 2):S171-6. doi: 10.1016/s0002-8703(99)70339-x. Am Heart J. 1999. PMID: 10426878 Review.
-
Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).Am J Cardiol. 1998 Oct 22;82(8B):63P-68P. doi: 10.1016/s0002-9149(98)00664-x. Am J Cardiol. 1998. PMID: 9809894 Review.
-
[GPIIb/IIIa blockers for optimizing thrombolysis in acute myocardial infarct].Herz. 2001 Apr;26 Suppl 1:42-5. doi: 10.1007/pl00014031. Herz. 2001. PMID: 11349626 Review. German.
-
Safety and tolerability of abciximab in patients with acute myocardial infarction and failed thrombolysis.Int J Cardiol. 2003 Dec;92(2-3):265-70. doi: 10.1016/s0167-5273(03)00085-8. Int J Cardiol. 2003. PMID: 14659863 Clinical Trial.
-
[Optimal thrombolysis].Z Kardiol. 2001 Aug;90(8):591-5. doi: 10.1007/s003920170129. Z Kardiol. 2001. PMID: 11565215 German.
Cited by
-
Optimizing the use of thrombolytics in ST-segment elevation myocardial infarction.Drugs. 2009 Oct 1;69(14):1945-66. doi: 10.2165/11317670-000000000-00000. Drugs. 2009. PMID: 19747010 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
